Arcturus Therapeutics
ARCT | NASDAQ
$8.31
-$0.05 (-0.60%)
At close: Nov 16, 2026, 4:00 PM ET
$8.31
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-0.60%
(1D)No price chart data available for 1D timeframe.
Rating
39.5
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #539/1021 (Top 53%)
Key Statistics
Market Data
Market Cap $239.51M
1D Range
8.28 9.78
52W Range
5.53 16.93
Valuation (TTM)
PE -2.68
PB 1.42
EV/EBITDA -0.93
Valuation (NTM)
Forward PE N/A
Forward PEG -0.06
Price Target $30.50
Cash Flow
FCF Yield -26.1%
SBC Adj. FCF Yield -34.3%
SBC Impact -31.0%
Margins
Gross Margin 97.4%
Operating Margin -384.1%
FCF Margin -251.0%
Growth (CAGR)
Revenue 3Y | 5Y -56.1% |
23.2%
Dil EPS 3Y | 5Y -17.0% |
-5.9%
FCF 3Y | 5Y -0.8% |
6.9%
Returns
ROA -40.5%
ROE -46.8%
ROIC -50.3%
Financial Health
Net Cash
$166.57M
Current Ratio 6.68
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respira...
Sector Healthcare
Industry Biotechnology
Employees 109
IPO Date May 22, 2013
Website arcturusrx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.26
Beat +62.13%
YoY:
+46.94% REV
$18.3M
Beat +128.80%
YoY:
+6.68%Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$30.50
Upside
+267.03%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ARCT